Postnatal onset of severe growth retardation after in utero exposure to carbamazepine and phenobarbital: a case report
Postnatal onset of severe growth retardation after in utero exposure to carbamazepine and phenobarbital: a case report
Journal of Medical Case Reports 2009, 3:7300
Published: August 2009
Published: August 2009
Introduction:
Anticonvulsant drugs taken by pregnant women to prevent seizures are among the most common causes of potential harm to the fetus. While the immediate harmful effects manifesting as congenital abnormalities are well known, the long-term effects on growth of children exposed in utero to antiepileptic drugs are still uncertain.
Case presentation:
A 7-year-old boy presented to our clinic with severe short stature. His height was 110.4 cm (−2.4 standard deviation score), with a target height of 177 cm (+0.35 standard deviation score). Height corrected for target height was −2.75 standard deviation score. He presented with mild dysmorphic facial features, hypospadias and postnatal onset of severe growth retardation. Biochemical and endocrine tests were in the normal range. The child was exposed in utero to both carbamazepine and phenobarbital.
Conclusion:
This case report shows for the first time that prenatal exposure to antiepileptic drugs may induce postnatal onset of severe growth retardation, suggesting the need for growth and endocrine monitoring of offspring exposed in utero to anticonvulsant drugs.
Introduction
Epilepsy is common, affecting 0.5% to 1% of the population. Of these, a third are women in reproductive age, and approximately 1 in 250 pregnancies are exposed to antiepileptic drugs. In utero exposure to antiepileptic drugs can result in several different teratogenic effects including major malformations, dysmorphic facial features, intrauterine growth retardation, learning and behavioral problems. We report on a child exposed in utero to both carbamazepine and phenobarbital. He presented with mild dysmorphic facial features, hypospadias and postnatal onset of growth retardation.
References:
- Kini U, Adab N, Vinten J, Fryer A, Clayton-Smith J: Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsivant syndromes. Arch Dis Child Fetal Neonatal Ed 2006, 91:90-95.
- Meador KJ, Baker GA, Finnel RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC for the NEAD Study Group: In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006, 67:407-412.
- Artama M, Auvinen A, Raudaskoski T, Isojärvi I, Isojärvi J: Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005, 64:1874-1878.
- Manent JB, Jorquera I, Mazzucchelli I, Depaulis A, Perucca E, Ben- Ari Y, Represa A: Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia 2007, 48:684-693.
- Wide K, Winbladh B, Tomson T, Kallen B: Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25 years. Epilepsia 2000, 41:854-861.
- Perucca E: Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005, 4:781-786.
- Arulmozhi T, Dhanaraj M, Rangaraj R, Vengatesan A: Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurol India 2006, 54:42-47.
- Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, Ryan LM: The teratogenicity of anticonvulsant drugs. N Engl J Med 2001, 344:1132-1138.
